Immunotherapy: Open Access
Open Access

Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK

Biography

Helen Angell is a Director in the Oncology, Translational Science team in Cambridge, UK. Helen received her Ph.D. ‘Immune Modulation of the Tumour Microenvironment’ from the University of Nottingham School of Pharmacy, funded by AstraZeneca and EPSRC (Engineering and Physical Sciences Research Council). Upon completing her doctorate, Helen began working in the Laboratory of Integrative Immunology at the Cordeliers Research Centre, Paris. A joint MedImmune-funded postdoc, here Helen was involved in the development and implementation of the ‘Immunoscore

Publications

• Research   
  Multiplex Immunohistochemistry: The Importance of Staining Order When Producing a Validated Protocol
  Author(s): Jihad Syed, Jack Ashton, Jesuchristopher Joseph, Gemma N Jones, Christian Slater, Alan Sharpe, Garry Ashton, William Howat, Richard Byers and Helen K Angell*
  
  Aim: The complexity of multifactorial diseases, such as cancer, poses significant challenges to the development of personalised therapies. Integrated digital histological analysis of tumours provides a better understanding of the immune microenvironment and the prognostic relationship associated with the enumeration and distribution of specific tumour infiltrating lymphocyte (TILs) subpopulations. To this effect multiplex cell labelling , alongside multi-spectral imaging (MSI) is an approach increasingly used to achieve more accurate in-situ TIL phenotyping and quantification. However, these approaches require full validation prior to utilisation , which is the fundamental aim of this study. Methods: Whole sections and tissue microarrays of lymphocyte-rich tissue were used to develop and validate a multiplex immunofluorescence (IF) protocol .. View More»
  

  Abstract HTML PDF